WILMETTE, Ill., June  26, 2026  (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (&#34;Monopar&#34; or the &#34;Company&#34;) (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for

MNPR

Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease

Monopar's ALXN1840 shows sustained neurologic gains; NDA targeted mid-2026

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>WILMETTE, Ill., June  26, 2026  (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (&amp;#34;Monopar&amp;#34; or the &amp;#34;Company&amp;#34;) (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Monopar Therapeutics announced new Phase 3 FoCus analyses showing ALXN1840 delivers meaningful neurologic and global clinical improvements versus standard of care in Wilson disease. Key measures, including UWDRS Part III and CGI-I at Week 48, favored ALXN1840 with robust safety (SAEs 4.9%, no deaths) across 266 patients. The company plans an FDA NDA submission in mid-2026, positioning ALXN1840 as a potential first-in-class therapy if approved.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>FoCus Phase 3 data show ALXN1840 improves neurologic outcomes vs SoC.</li><li>UWDRS Part III and CGI-I Week 48 show significant benefit (p=0.006; p&lt;0.001).</li><li>NDA submission to FDA planned mid-2026; safety profile favorable in 266 patients.</li><li>Poster at EAN 2026 supports continued neurologic improvement over 48 weeks.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Monopar Therapeutics Inc. (MNPR)</strong>: Positive FoCus Phase 3 data support mid-2026 FDA NDA submission; potential upside if approved.</li><li><strong>Adolphe de Rothschild Foundation Hospital (N/A)</strong>: Investigators presented analyses; not a publicly traded company, limited direct market impact.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category fits Corporate Developments as a clinical-stage biotech pushing an NDA; signals regulatory and pipeline catalysts.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Upcoming EAN 2026 presentation reinforces positive FoCus data and press visibility.</li><li>FDA NDA submission anticipated mid-2026; potential near-term price catalyst.</li><li>Strong safety profile supports upside; 266 patients with long exposure reduce risk.</li><li>Remains a near-term catalyst-driven stock potential on regulatory milestones.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Phase 3 FoCus subset n=207 with neurologic symptoms at baseline.</li><li>UWDRS Part III improvement significant for ALXN1840 (p=0.006).</li><li>CGI-I Week 48 validation favoring ALXN1840 (p&lt;0.001).</li><li>Across phases 2/3: 266 patients, 645 patient-years; median 2.58 years; max &gt;8 years.</li><li>Drug-related SAEs 4.9%; neurologic SAEs &lt;1%; no treatment-related deaths.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>MNPR could rally on NDA timing and positive EAN data; near-term catalyst in mid-2026.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>WILMETTE, Ill., June  26, 2026  (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/MNPR">MNPR</a>), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that new analyses from the Phase 3 FoCus randomized controlled clinical trial of ALXN1840 (tiomolibdate choline, TMC) will be presented at the 12th Congress of the European Academy of Neurology (EAN 2026), June 27–30, 2026, in Geneva, Switzerland. These analyses build upon the previously reported Phase 3 FoCus results demonstrating ALXN1840 met its primary endpoint of superior copper mobilization versus standard of care.</p>  <p>In an encore poster presentation titled "Greater clinical benefit with tiomolibdate choline versus standard of care in neurologic Wilson disease patients in the Phase 3 FoCus Trial," Aurélia Poujois, MD, PhD, Department of Neurology, Adolphe de Rothschild Foundation Hospital, Paris, France, will present results showing that ALXN1840 produced significant neurologic improvement over time and greater global clinical improvement compared to standard-of-care (SoC) therapy in Wilson disease (WD) patients with neurologic symptoms at baseline. ALXN1840 also demonstrated similar or better outcomes compared to SoC across a range of psychiatric and hepatic measures during the 48-week study.</p>  <p><strong>Key findings presented at EAN 2026:<br></br></strong>In the subset of patients with neurologic symptoms at baseline from the 2:1 randomized Phase 3 FoCus clinical trial (NCT03403205; n=207), ALXN1840 demonstrated improved outcomes compared to SoC across multiple clinical measures:</p>  <ul type="disc"><li>Neurologic improvement on the rater-blinded, physician-assessed Unified Wilson Disease Rating Scale (UWDRS) Part III was significant and continued over time with ALXN1840 (p=0.006) but not with SoC (p=0.435).</li><li>Global clinical improvement as assessed by the Clinical Global Impressions – Improvement (CGI-I) scale at Week 48 was significantly greater with ALXN1840 than with SoC (p&lt;0.001).</li><li>A greater proportion of patients treated with ALXN1840 achieved improvement on the rater-blinded UWDRS Part III at Week 48 compared with SoC, with consistent results observed across multiple improvement thresholds.</li><li>ALXN1840 also produced similar or greater improvement than SoC at Week 48 across psychiatric and hepatic measures.<br></br><br></br></li></ul>  <p>Across Phase 2 and Phase 3 studies, ALXN1840 has demonstrated a well-characterized and favorable safety profile in 266 patients, with a median treatment duration of 2.58 years and maximum exposure of more than 8 years. Drug-related serious adverse events (SAEs) occurred in 4.9% of patients, including neurologic SAEs in less than 1% and no treatment-related deaths.</p>  <p>"For Wilson disease patients with neurologic symptoms, meaningful improvement can be difficult to achieve with existing therapies, and some patients experience severe paradoxical worsening," said Dr. Poujois. "These new analyses from the Phase 3 FoCus trial are encouraging because they show that ALXN1840 treatment was associated with continued neurologic improvement over time and greater global clinical benefit compared with standard of care."</p>  <p>The poster (<a href="https://www.globenewswire.com/Tracker?data=lfF02lPlpmMOjMW97RyR7jX3uhBRh1_Z_MMyvxRqx2TGO6kAOVSlaCP-IOxaJctZadFEYjpV8jjoeM6wFIyDM9QGnuJyKfIQZmu1Olk1E6JzgTZ1mtLPbKNnGDz8eGbC" rel="nofollow" target="_blank">link</a>) is available on Monopar’s website.</p>  <p>These findings further support Monopar’s planned New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for ALXN1840 in mid-2026.</p>  <p><strong>About Wilson Disease<br></br></strong>Wilson disease (WD) is a rare genetic disorder that affects approximately 1 in 30,000 people worldwide. It is caused by mutations in the ATP7B gene, which impairs the body’s ability to excrete copper. It is characterized by toxic accumulation of copper in the liver, brain, and other organs, leading to progressive and potentially fatal outcomes if untreated.</p>  <p><strong>About ALXN1840<br></br></strong>ALXN1840 (tiomolibdate choline, TMC) is a novel first-in-class albumin tripartite complex (ATC) activator under investigation for the treatment of Wilson disease. ALXN1840 rapidly mobilizes and tightly sequesters excess copper in ATCs, suppressing its redox reactivity, limiting oxidative damage, and blocking transport across the blood–brain barrier. Clinical data demonstrate that ALXN1840 improves copper balance by increasing fecal copper excretion. In the Phase 3 pivotal trial, ALXN1840 met the primary endpoint by demonstrating rapid and sustained copper mobilization significantly greater than standard of care over 48 weeks in both previously treated and untreated patients. Durable clinical improvement and a favorable safety and tolerability profile were observed across 645 patient-years of follow-up in 266 patients.</p>  <p><strong>About Monopar Therapeutics Inc.<br></br></strong>Monopar Therapeutics is a clinical-stage biopharmaceutical company with late-stage ALXN1840 for Wilson disease, and radiopharmaceutical programs including MNPR-101-Zr (Phase 1) for imaging advanced cancers along with MNPR-101-Lu (Phase 1a) and MNPR-101-Ac (late preclinical) for the treatment of advanced cancers. For more information, visit: <a href="https://www.globenewswire.com/Tracker?data=6S1b310WFNW5FnqDU0G6HiXOrX-YDN9hZY4-e2PIhDEvyppa0Bh-_VPuZzcCG4pJOArjkO-mAVtNx1GxqszgMbCDS9_afOVrsYFLFSdoHaE=" rel="nofollow" target="_blank">www.monopartx.com</a>.</p>  <p><strong>Forward-Looking Statements<br></br></strong>Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. An example of a forward-looking statement includes the statement concerning: that these findings (the Phase 3 FoCus data) further support Monopar’s planned New Drug Application (NDA) submission to the FDA for ALXN1840 in mid-2026. The forward-looking statements involve risks and uncertainties including, but not limited to: uncertainties related to the regulatory process that Monopar intends to initiate related to ALXN1840 and the outcome thereof; the rate of market acceptance and competitiveness in terms of pricing, efficacy and safety, of any products for which Monopar receives marketing approval, and Monopar’s ability to competitively market any such products as compared to larger pharmaceutical firms; Monopar’s ability to raise sufficient funds in order for the Company to support continued preclinical, clinical, regulatory, precommercial and commercial development of its programs and to make contractual milestone payments, as well as its ability to further raise additional funds in the future to support any existing or future product candidate programs through completion of clinical trials, the approval processes and, if applicable, commercialization; and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of imaging agents and therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.</p>  <p><strong>CONTACT:</strong></p>  <p><strong>Monopar Therapeutics Inc.</strong><br></br>Investor Relations<br></br>Quan Vu<br></br>Chief Financial Officer<br></br>vu@monopartx.com</p>  <p>Follow Monopar on social media for updates:<br></br>X: @MonoparTx   LinkedIn: Monopar Therapeutics</p>  <p>Source: Monopar Therapeutics Inc.</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTc1Mjk2MiM3Njc5Mzg3IzIxOTM4NjM="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/OTZmOGM1OGEtNDQ4Yi00ODAyLWE4N2QtNWFkMWM2YjhhYjg4LTEyMDU0MTYtMjAyNi0wNi0yNi1lbg==/tiny/Monopar-Therapeutics-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/f8cee181-5ae9-4a02-84f5-6e35affbb72b"><img src="https://ml.globenewswire.com/media/f8cee181-5ae9-4a02-84f5-6e35affbb72b/small/monopartherapeuticsinc-png.png" border="0" width="150" height="28" alt="Primary Logo"></img></a></p>

Monopar Therapeutics announced new Phase 3 FoCus analyses showing ALXN1840 delivers meaningful neurologic and global clinical improvements versus standard of care in Wilson disease. Key measures, including UWDRS Part III and CGI-I at Week 48, favored ALXN1840 with robust safety (SAEs 4.9%, no deaths) across 266 patients. The company plans an FDA NDA submission in mid-2026, positioning ALXN1840 as a potential first-in-class therapy if approved.

monopar-presents-new-analyses-of-phase-3-focus-data-at-ean-2026-showing-greater-neurologic-and-global-clinical-benefit-with-alxn1840-versus-standard-of-care-in-wilson-disease

Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News